Cargando…
Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
We investigated whether responses to as-needed intravitreal aflibercept injections (IAIs) for polypoidal choroidal vasculopathy (PCV) differed among patients based upon drusen characteristics in fellow eyes. 110 eyes from 110 patients with PCV received 3 monthly IAI and thereafter Pro re nata (PRN)...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463500/ https://www.ncbi.nlm.nih.gov/pubmed/32752023 http://dx.doi.org/10.3390/jcm9082459 |
_version_ | 1783577146287980544 |
---|---|
author | Fukuda, Yoshiko Sakurada, Yoichi Sugiyama, Atsushi Yoneyama, Seigo Matsubara, Mio Kikushima, Wataru Tanabe, Naohiko Parikh, Ravi Kashiwagi, Kenji |
author_facet | Fukuda, Yoshiko Sakurada, Yoichi Sugiyama, Atsushi Yoneyama, Seigo Matsubara, Mio Kikushima, Wataru Tanabe, Naohiko Parikh, Ravi Kashiwagi, Kenji |
author_sort | Fukuda, Yoshiko |
collection | PubMed |
description | We investigated whether responses to as-needed intravitreal aflibercept injections (IAIs) for polypoidal choroidal vasculopathy (PCV) differed among patients based upon drusen characteristics in fellow eyes. 110 eyes from 110 patients with PCV received 3 monthly IAI and thereafter Pro re nata (PRN) IAI over 12 months. Patients were classified into 4 groups depending on fellow eye findings. Group 1 (n = 16): pachydrusen; Group 2 (n = 45): no drusen; Group 3 (n = 35): soft drusen; Group4 (n = 14) PCV/scarring. Best-corrected visual acuity improved at 12 months in all groups, but not significantly in Group 1 and Group 4; however, visual improvement was similar among the groups after adjusting baseline confounders. Group 1 had a significantly lower percentage of eyes needing retreatment (all p < 0.001; Group 1: 16.7%; Group 2: 50.8%; Group 3: 80%; Group 4: 85.7%). The mean number of retreatments was least in Group 1 among the groups (all p-value < 0.003; Group 1: 0.50 ± 1.32; Group 2: 1.73 ± 2.08; Group 3:2.71 ± 1.99; Group 3: 2.71 ± 2.16). Patients with pachydrusen in fellow eyes were less likely to require additional IAI following the loading dose and may be ideal candidates for aflibercept monotherapy in their first year. |
format | Online Article Text |
id | pubmed-7463500 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74635002020-09-04 Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy Fukuda, Yoshiko Sakurada, Yoichi Sugiyama, Atsushi Yoneyama, Seigo Matsubara, Mio Kikushima, Wataru Tanabe, Naohiko Parikh, Ravi Kashiwagi, Kenji J Clin Med Article We investigated whether responses to as-needed intravitreal aflibercept injections (IAIs) for polypoidal choroidal vasculopathy (PCV) differed among patients based upon drusen characteristics in fellow eyes. 110 eyes from 110 patients with PCV received 3 monthly IAI and thereafter Pro re nata (PRN) IAI over 12 months. Patients were classified into 4 groups depending on fellow eye findings. Group 1 (n = 16): pachydrusen; Group 2 (n = 45): no drusen; Group 3 (n = 35): soft drusen; Group4 (n = 14) PCV/scarring. Best-corrected visual acuity improved at 12 months in all groups, but not significantly in Group 1 and Group 4; however, visual improvement was similar among the groups after adjusting baseline confounders. Group 1 had a significantly lower percentage of eyes needing retreatment (all p < 0.001; Group 1: 16.7%; Group 2: 50.8%; Group 3: 80%; Group 4: 85.7%). The mean number of retreatments was least in Group 1 among the groups (all p-value < 0.003; Group 1: 0.50 ± 1.32; Group 2: 1.73 ± 2.08; Group 3:2.71 ± 1.99; Group 3: 2.71 ± 2.16). Patients with pachydrusen in fellow eyes were less likely to require additional IAI following the loading dose and may be ideal candidates for aflibercept monotherapy in their first year. MDPI 2020-07-31 /pmc/articles/PMC7463500/ /pubmed/32752023 http://dx.doi.org/10.3390/jcm9082459 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fukuda, Yoshiko Sakurada, Yoichi Sugiyama, Atsushi Yoneyama, Seigo Matsubara, Mio Kikushima, Wataru Tanabe, Naohiko Parikh, Ravi Kashiwagi, Kenji Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy |
title | Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy |
title_full | Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy |
title_fullStr | Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy |
title_full_unstemmed | Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy |
title_short | Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy |
title_sort | pachydrusen in fellow eyes predict response to aflibercept monotherapy in patients with polypoidal choroidal vasculopathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463500/ https://www.ncbi.nlm.nih.gov/pubmed/32752023 http://dx.doi.org/10.3390/jcm9082459 |
work_keys_str_mv | AT fukudayoshiko pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy AT sakuradayoichi pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy AT sugiyamaatsushi pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy AT yoneyamaseigo pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy AT matsubaramio pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy AT kikushimawataru pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy AT tanabenaohiko pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy AT parikhravi pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy AT kashiwagikenji pachydruseninfelloweyespredictresponsetoafliberceptmonotherapyinpatientswithpolypoidalchoroidalvasculopathy |